AIMEDBIO

AimedBio and Sovargen Announce Joint AOC Development and Strategic Investment

Expanding ADC Capabilities to Explore the Potential of Gene-Regulating Therapeutics

SEOUL, South Korea – AimedBio announced today that it has entered into a joint development agreement and made a strategic equity investment in Sovargen, a company specializing in oligonucleotide therapeutics. The amount of the investment was not disclosed.

The core of this agreement is to explore the potential of expanding from Antibody-Drug Conjugates (ADC) to Antibody-Oligonucleotide Conjugates (AOC), which can regulate gene expression. This will be achieved by combining AimedBio’s expertise in antibody and target discovery, based on its patient-derived cell platform, with Sovargen’s advanced oligonucleotide design and manufacturing technology. The two companies plan to explore the applicability of AOC technology to various fields, including oncology, metabolic diseases, immune disorders, and rare diseases.

Sovargen, led by co-CEOs Jeong-ho Lee and Cheolwon Park, is a specialized oligonucleotide company that has proven its global competitiveness. It recently signed a technology transfer agreement with the Italian pharmaceutical company Angelini Pharma for an antisense oligonucleotide (ASO) treatment for epilepsy, a deal valued at up to ₩750 billion.

"Through this joint development and strategic cooperation, we will maximize the technological synergy between our two companies," stated an official from AimedBio. "Building on our existing ADC capabilities, we will continue to pursue technological expansion into next-generation modalities."

-END-